标准化耐多药肺结核化疗方案的不良反应及治疗转归情况分析

发布时间：2018-04-03 10:47

本文选题：结核　切入点：肺　出处：《中华疾病控制杂志》2014年07期

【摘要】：目的分析江苏省标准化耐多药肺结核化疗方案不良反应发生情况及其对治疗转归的影响,为全省开展耐多药肺结核防治工作提供经验。方法选择江苏省两市采用标准化耐多药肺结核化疗方案治疗、且有明确治疗转归的81例耐多药肺结核患者为研究对象,对患者治疗后发生不良反应情况开展调查,并对不同治疗转归的患者进行统计分析。结果 89例完成治疗的患者中,81例(91.0%)使用标准化治疗方案,其中出现不良反应患者数为50例(61.7%)。发生不良反应的患者治疗依从率为76.0%,未发生不良反应的患者治疗依从率为90.3%,两者间差异无统计学意义(醊2=2.60,P=0.107)。发生不良反应的患者治疗成功率为56.0%,而未发生不良反应的患者治疗成功率为80.6%,两者间差异有统计学意义(醊2=5.14,P=0.023)。结论标准化抗结核方案在临床治疗中值得推广使用,但患者的不良反应率稍高,此研究对全省耐多药工作提供一定的参考价值。
[Abstract]:Objective to analyze the adverse reactions of standardized multidrug resistant pulmonary tuberculosis (MDR-TB) regimen in Jiangsu Province and its influence on the outcome of treatment, and to provide experience for the prevention and treatment of MDR-TB in Jiangsu province.Methods 81 cases of MDR-TB patients who were treated with standardized multi-drug resistant pulmonary tuberculosis chemotherapy regimen in two cities of Jiangsu Province were selected as the study objects. The adverse reactions of the patients were investigated after treatment.Statistical analysis was made on the patients with different therapeutic outcomes.Results among the 89 patients who had completed the treatment, 81 patients were treated with standardized treatment regimen, of which 50 patients had adverse reactions (61.7%).The therapeutic compliance rate of the patients with adverse reactions was 76.0 and that of the patients without adverse reactions was 90.30.There was no significant difference between the two groups.The successful rate of treatment in patients with adverse reactions was 56.0, while that in patients without adverse reactions was 80.6. The difference between the two groups was statistically significant (P < 0.05. 14, P < 0. 023).Conclusion the standardized anti-tuberculosis regimen is worth popularizing in clinical treatment, but the adverse reaction rate of the patients is a little higher. This study provides a certain reference value for the work of multi-drug resistance in the whole province.
【作者单位】：江苏省疾病预防控制中心慢性传染病防治所;
【基金】：卫生部科研基金(W201208)
【分类号】：R521

【相似文献】